Pharmaceuticals · CONCORDB
Pharma - API & CRAMS
from 1,446 today
Concord Biotech Ltd. is an R&D-driven biopharma company specializing in APIs and finished formulations across therapeutic areas such as immunosuppressants, oncology, and anti-infectives. The brokerage highlights catalysts including the new injectable facility, the acquisition of Stellon Biotech, and strong 1QFY27 performance with expanding margins.
Revenue grew 26% YoY to INR 2.6bn driven by 42% YoY API growth, partly offset by 23% decline in formulations. EBITDA margin expanded 190bps YoY to 32%.
Concord Biotech reported a broadly in-line 1QFY27 performance driven by API growth, while injectables and Stellon Biotech are expected to drive the next leg of growth. We maintain our BUY rating with a revised target price of INR 1,700 based on 32x 1HFY29E EPS.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
